Amoxycillin Potassium Clavulanate Tablet (MOXIFED-CV-KID)

Amoxycillin Potassium Clavulanate Tablet (MOXIFED-CV-KID): A Trusted Solution for Pediatric Bacterial Infections

Children are especially vulnerable to bacterial infections due to their developing immune systems. From respiratory tract infections to ear and urinary tract infections, timely and effective treatment is crucial to prevent complications. MOXIFED-CV-KID, a combination of Amoxycillin and Potassium Clavulanate, is a widely trusted antibiotic formulation designed specifically for pediatric patients. It combines a broad-spectrum penicillin antibiotic with a beta-lactamase inhibitor, offering enhanced efficacy against resistant bacterial strains.

This article provides a comprehensive overview of MOXIFED-CV-KID, including its composition, mechanism of action, indications, dosage, safety profile, and its role in pediatric antimicrobial therapy.

Composition and Formulation

MOXIFED-CV-KID is a fixed-dose combination containing:

• Amoxycillin Trihydrate: Equivalent to Amoxycillin 200 mg
   

• Potassium Clavulanate: Equivalent to Clavulanic Acid 28.5 mg
   

This formulation is tailored for children and is often available in dispersible or chewable tablet forms to ensure ease of administration and improved compliance.

How it works?

Amoxycillin is a broad-spectrum beta-lactam antibiotic that works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. However, many bacteria produce beta-lactamase enzymes that can inactivate amoxycillin.

Clavulanic acid, a beta-lactamase inhibitor, binds to and neutralizes these enzymes, thereby restoring the efficacy of amoxycillin against resistant bacterial strains. This synergistic combination significantly expands the antibacterial spectrum and is effective against both gram-positive and gram-negative organisms.

Indications

MOXIFED-CV-KID is indicated for the treatment of a wide range of bacterial infections in children, including:

1. Upper Respiratory Tract Infections
    

   • Tonsillitis, pharyngitis, sinusitis
      

2. Lower Respiratory Tract Infections
    

   • Bronchitis, pneumonia
      

3. Ear, Nose, and Throat Infections
    

   • Otitis media
      

4. Urinary Tract Infections (UTIs)
    

   • Cystitis, pyelonephritis
      

5. Skin and Soft Tissue Infections
    

   • Impetigo, cellulitis
      

6. Dental Infections
    

   • Abscesses and periodontal infections
      

7. Bone and Joint Infections
    

   • Osteomyelitis (in some cases, under medical supervision)
      

Dosage and Administration

The dosage of MOXIFED-CV-KID should be based on the child's age, weight, and severity of infection. A typical pediatric dose may range between:

• 25 to 45 mg/kg/day in divided doses, depending on the severity.
   

For example:

• For mild to moderate infections: 25 mg/kg/day
   
• For severe infections: 45 mg/kg/day
   

It is important that caregivers follow the pediatrician’s guidance strictly, especially regarding duration of therapy to avoid sub-therapeutic exposure or antibiotic resistance.

Advantages of MOXIFED-CV-KID

1. Enhanced Spectrum of Activity
   The addition of clavulanic acid broadens the efficacy against resistant pathogens, making the treatment more reliable in clinical settings.
    
2. Pediatric-Friendly Formulation
   Designed in palatable forms such as flavored tablets or dispersible tablets, which improve adherence among children.
    
3. Reduced Risk of Resistance
   Effective against beta-lactamase producing strains, which are increasingly common in pediatric infections.
    
4. Well-Tolerated Profile
   Most children tolerate MOXIFED-CV-KID well, with manageable side effects when taken as prescribed.
    

Pharmacokinetics

• Absorption: Amoxycillin and Clavulanate are well absorbed orally. The bioavailability is optimal when taken at the start of a meal.
   
• Distribution: Widely distributed in body tissues and fluids, including the lungs, middle ear, and urinary tract.
   
• Elimination: Primarily excreted via the kidneys. Dose adjustments may be necessary in children with renal impairment.

Safety and Side Effects

Though generally safe, MOXIFED-CV-KID may cause some side effects, including:

• Common: Nausea, diarrhea, abdominal discomfort, skin rash
   
• Rare: Hepatotoxicity, allergic reactions (anaphylaxis), superinfection (e.g., candidiasis)
   

Precautions:

• Children with a history of penicillin allergy should not take this medication.
   
• Liver function and renal function should be monitored in prolonged use.
   

Contraindications

• Hypersensitivity to penicillins or cephalosporins
   
• History of cholestatic jaundice or hepatic dysfunction associated with amoxycillin/clavulanate
   
• Severe renal impairment (without dose adjustment)
   

Storage and Handling

• Store in a cool, dry place away from direct sunlight.
   
• Keep out of reach of children.
   
• Ensure the dispersible tablet is used immediately after preparation to maintain efficacy.
   

Role in Pediatric Antibiotic Stewardship

MOXIFED-CV-KID plays an important role in antibiotic stewardship programs. By combining amoxycillin with a beta-lactamase inhibitor, this formulation reduces the need for higher-generation antibiotics, thereby slowing resistance development.

Healthcare professionals should ensure its use aligns with local antibiogram data and established clinical guidelines, avoiding unnecessary or overuse in viral infections.

Market Position and Brand Trust

MOXIFED-CV-KID, as marketed by Monark Biocare, is trusted for its high-quality formulation, stringent quality control, and pediatric suitability. The brand ensures consistent therapeutic outcomes, contributing to better health outcomes in children.

Monark Biocare focuses on delivering safe, effective, and affordable medications tailored to pediatric care. Their commitment to quality and innovation is reflected in MOXIFED-CV-KID’s popularity among pediatricians and parents alike.

Conclusion

MOXIFED-CV-KID is a robust solution in the pediatric arsenal against bacterial infections. With its powerful combination of amoxycillin and potassium clavulanate, it addresses both susceptible and resistant strains effectively. Its child-friendly formulation, broad spectrum, and favorable safety profile make it a go-to choice for pediatricians treating common and complicated infections.

However, like all antibiotics, it should be used judiciously under medical supervision to ensure safety and efficacy while preserving the usefulness of this vital treatment for future generations.